The cancer theory of pulmonary arterial hypertension

PVRI Member Authors: Dr. Olivier Boucherat, Steeve Provencher, Sebastien Bonnet

Abstract

Pulmonary arterial hypertension (PAH) remains a mysterious killer that, like cancer, is characterized by tremendous complexity. PAH development occurs under sustained and persistent environmental stress, such as inflammation, shear stress, pseudo-hypoxia, and more. After inducing an initial death of the endothelial cells, these environmental stresses contribute with time to the development of hyper-proliferative and apoptotic resistant clone of cells including pulmonary artery smooth muscle cells, fibroblasts, and even pulmonary artery endothelial cells allowing vascular remodeling and PAH development. Molecularly, these cells exhibit many features common to cancer cells offering the opportunity to exploit therapeutic strategies used in cancer to treat PAH. In this review, we outline the signaling pathways and mechanisms described in cancer that drive PAH cells’ survival and proliferation and discuss the therapeutic potential of antineoplastic drugs in PAH.

Read the full article online

Topics

Pulmonary Arterial Hypertension

Authors

Olivier Boucherat, Geraldine Vitry, Isabelle Trinh, Roxane Paulin, Steeve Provencher, Sebastien Bonnet

Published in:

Pulmonary Circulation Vol 7: No 2 cover image

May 2017

Pulmonary Circulation Vol 7: No 2

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg